ArticleJournal of diabetes science and technology2007
Inflammation and glucose sensors: use of dexamethasone to extend glucose sensor function and life span in vivo.
Article in Journal of diabetes science and technology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Subdermal Insertable Sensors for Health Monitoring: Applications, Challenges, and Emerging Technologies.Annals of biomedical engineering · 2026Review
- Injury to tissue caused by device penetration of the skin triggers formation of extracellular traps.Communications biology · 2025Article
- Impact of Bindarit, a CCL2 Chemokine Synthesis Inhibitor, on Macrophage-Based Biofouling and Continuous Glucose MonitoringBiosensors & bioelectronics: X · 2024Article
- Selective Immunosuppression Targeting the NLRP3 Inflammasome Mitigates the Foreign Body Response to Implanted Biomaterials While Preserving Angiogenesis.Advanced healthcare materials · 2023Article
- Biomedical Implants with Charge-Transfer Monitoring and Regulating Abilities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Modulating the foreign body response of implants for diabetes treatment.Advanced drug delivery reviews · 2021Review
- Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation.Journal of diabetes science and technology · 2021Review
- Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases.GeroScience · 2020Article
- Dexamethasone-Enhanced Microdialysis and Penetration Injury.Frontiers in bioengineering and biotechnology · 2020Review
- Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer.Nature biomedical engineering · 2018Article
- Crosslinked basement membrane-based coatings enhance glucose sensor function and continuous glucose monitoring in vivo.Journal of biomedical materials research. Part A · 2018Article
- In Vivo Chemical Sensors: Role of Biocompatibility on Performance and Utility.Analytical chemistry · 2017Review
- Impact of CCL2 and CCR2 chemokine/receptor deficiencies on macrophage recruitment and continuous glucose monitoring in vivo.Biosensors & bioelectronics · 2016Article
- Porous, Dexamethasone-loaded polyurethane coatings extend performance window of implantable glucose sensors in vivo.Acta biomaterialia · 2016Article
- Effects of delayed delivery of dexamethasone-21-phosphate via subcutaneous microdialysis implants on macrophage activation in rats.Acta biomaterialia · 2015Article
- Characterization of porous, dexamethasone-releasing polyurethane coatings for glucose sensors.Acta biomaterialia · 2014Article
- Microdialysis sampling techniques applied to studies of the foreign body reaction.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2014Review
- Role of interleukin-1/interleukin-1 receptor antagonist family of cytokines in long-term continuous glucose monitoring in vivo.Journal of diabetes science and technology · 2013Article
- Biocompatible materials for continuous glucose monitoring devices.Chemical reviews · 2013Review
- Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on sensor performance and the foreign body response-part I: theoretical framework.Journal of diabetes science and technology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been generally accepted that the acute loss of sensor function is the consequence of sensor biofouling as a result of inflammation induced at sites of sensor implantation, as well as tissue trauma induced by the sensor and its implantation. Because anti-inflammatory therapies are used routinely to control inflammation in a wide variety of diseases, we hypothesized that anti-inflammatory therapy would likely extend glucose sensor function in vivo. To test this hypothesis, we utilized our recently developed mouse model of implantable glucose sensors and the potent anti-inflammatory steroid dexamethasone (DEX).
methodFor this study, glucose sensors were implanted subcutaneously into the head and neck area of mice and sensor function was determined up to 14 days postimplantation. These mice received a daily intraperitoneal injection of DEX at a dose of 1, 6, or 10 mg/kg body weight.
resultsMice not treated with DEX lost sensor functionality very rapidly, usually within the first 24 hours postimplantation. Mice treated with DEX at the various doses had an increased sensor life span of up to 2 weeks postimplantation. Additionally, sensitivity was maintained in DEX-treated mice as compared to control mice (non-DEX treated). Histologic evaluation of tissue surrounding the site of sensor implantation had almost no inflammatory cells in DEX-treated mice, whereas control mice had an intense band of inflammation surrounding the site of sensor implantation.
conclusionTo our knowledge this is the first study directly demonstrating that anti-inflammatory therapy can extend glucose sensor function in vivo and supports the key role of inflammation in loss of sensor function in vivo, as well as the uses of anti-inflammatory therapy as a potential key adjuvant in enhancing glucose sensor function and life span in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.